Collectively, these findings reinforce the robust antitumor activity and therapeutic potential of 177Lu-PSMA-617 in targeting PSMA-expressing prostate cancer, supporting its continued development for clinical application. The gene discussed is FOLH1; the disease is prostate carcinoma.